MedTrace Logo

Continuous Delivery of Levodopa in Patients With Advanced Idiopathic Parkinsons Disease - Cost-benefit

NCT00272688 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2015-12-30

No results posted yet for this study

Summary

An open, observational health economic study to estimate marginal cost and health consequences of replacing conventional Parkinsons disease therapy with intraduodenal levodopa administered continuously

Conditions

  • Parkinson Disease

Interventions

DRUG

Levodopa (drug), intraduodenal administration

Sponsors & Collaborators

  • Solvay Pharmaceuticals

    collaborator INDUSTRY

  • University Hospital, Akershus

    lead OTHER

Principal Investigators

  • Christofer Lundqvist, PhD, M.D. · HØKH - Helse Ost Health Services Research Centre, Akershus University Hospital, Norway

  • Antonie Beiske, PhD, M.D. · Dept Neurology, Akershus University Hospital, Norway

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2009-05-31
Completion
2009-05-31

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00272688 on ClinicalTrials.gov